February 28, 2014

As the Affordable Care Act approaches its four-year anniversary, its effects are still rippling through the economy and the healthcare marketplace. The legislation and concurrent recession has dramatically changed the dynamics of the pharmaceutical industry, rendering many business model assumptions obsolete. Understanding the implications of those changes for core processes like new product development and commercialization is critical to continued viability in biopharma.

That’s exactly what authors Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, Rita Numerof, Ph.D., President, and Michael Abrams, M.A., Managing Partner, set out to explore in The Affordable Care Act’s Impact on Innovation in Biopharma, published February 1, 2014, in BioPharm International. A regular feature of BioPharm International, this column provides a powerful summary of the impacts of the ACA, and offers strategic guidance for biopharma companies whose only choice is to adapt or fail.